Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 2/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20094228 | 0.79 | KDM4E (0.53) | CBFBHRH4EGLN1KDM4EALDH1A1 | |
| SCHEMBL125789 | 0.65 | CBFB (0.55) | CBFBKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL22452442 | 0.64 | HDAC6 (0.51) | CBFB | |
| SCHEMBL3469733 | 0.62 | CBFB (0.44) | CBFBHRH4EGLN1ALDH1A1 | |
| SCHEMBL27258711 | 0.60 | CBFB (0.46) | CBFBKDM4EALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL24141161 | 0.60 | CBFB (0.45) | CBFB | |
| SCHEMBL1192621 | 0.59 | EGLN1 (0.54) | CBFBHRH4EGLN1KDM4EALDH1A1 | |
| SCHEMBL15037628 | 0.56 | PARP1 (0.39) | KDM4EALDH1A1HPGD | |
| SCHEMBL1171206 | 0.52 | ALDH1A1 (0.67) | CBFBHRH4EGLN1KDM4EALDH1A1 | |
| SCHEMBL25223628 | 0.52 | OPRL1 (0.41) | CBFBHRH4KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351514-B2 | Benzimidazole inhibitors of the sodium channel | Mark G. DeGiacomo, Interim Trustee (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | DeGiacomo, Mark G. (US) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351514-B2 | Benzimidazole inhibitors of the sodium channel | SCN1A, KCNJ11, KCNJ1 | CBFB 3939/4885HRH4 597/4885EGLN1 1567/4885 |
| US-20180111894-A1 | Benzimidazole Inhibitors of the Sodium Channel | SCN1A, KCNJ11, KCNJ1 | CBFB 3939/4885HRH4 597/4885EGLN1 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.